Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature

详细信息    查看全文

• 作者：Paul R. Massey ; Jonathan S. Okman ; Julia Wilkerson…
• 关键词：Palmoplantar erythrodysesthesia ; Hand ; foot syndrome ; Hand ; foot skin reaction ; Toxic erythema of chemotherapy ; Tyrosine kinase inhibitor ; Vascular endothelial growth factor
• 刊名：Supportive Care in Cancer
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：23
• 期：6
• 页码：1827-1835
• 全文大小：1,341 KB
• 参考文献：1.Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276-312View Article PubMed Central PubMed
  2.Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15:1411-416View Article PubMed Central PubMed
  3.Balagula Y, Rosen ST, Lacouture ME (2011) The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 65:624-35View Article PubMed
  4.Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G (2005) Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 74:121-23View Article PubMed
  5.Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-96View Article PubMed
  6.Chu D, Lacouture ME, Fillos T, Wu S (2008) Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 47:176-86View Article PubMed
  7.Chu D, Lacouture ME, Weiner E, Wu S (2009) Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7:11-9View Article PubMed
  8.Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, Group TS (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-34View Article PubMed
  9.Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-318View Article PubMed
  10.Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280-289View Article PubMed
  11.Fischer A, Wu S, Ho AL, Lacouture ME (2013) The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 31:787-97View Article PubMed
  12.Gomez P, Lacouture ME (2011) Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 16:1508-519View Article PubMed Central PubMed
  13.Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443-457View Article PubMed
  14.Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-2View Article PubMed
  15.Janusch M, Fischer M, Marsch WC, Holzhausen HJ, Kegel T, Helmbold P (2006) The hand-foot syndrome—a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 16:494-99PubMed
  16.Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-795View Article PubMed Central PubMed
  17.Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-32View Article PubMed
  18.Lacouture ME, Reilly LM, Gerami P, Guitart J (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19:1955-961View Article PubMed
  19.Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-011View Article PubMed
  20.Lee JH, Chung YH, Kim JA, Shim JH, Lee D, Lee HC, Shin ES, Yoon JH, Kim BI, Bae SH, Koh KC, Park NH (2013) Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 119:136-42View Article PubMed
• 作者单位：Paul R. Massey (1)
  Jonathan S. Okman (2)
  Julia Wilkerson (3)
  Edward W. Cowen (4)
  
  1. Dell Medical School, The University of Texas at Austin, 601 E. 15th Street, CEC 2.470, Austin, TX, 78701, USA
  2. Department of Internal Medicine, Lankenau Medical Center, Philadelphia, PA, USA
  3. Medical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
  4. Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Nursing
  Nursing Management and Research
  Pain Medicine
  Rehabilitation Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-7339

文摘

Purpose Inhibition of the vascular endothelial growth factor receptor (VEGFR) with tyrosine kinase inhibitors (TKIs) is associated with cutaneous adverse effects that increase patient morbidity. Our objective was to examine the skin toxicity profile of anti-VEGFR TKIs and determine the changing incidence in clinical trials. Methods PubMed was queried for phase II or III trials of anti-VEGFR TKIs between 2000 and 2013 involving ?0 patients. Adverse events were abstracted, with results presented in both fixed and random effects models. Odds ratios (OR) and 95?% confidence intervals (CIs) were estimated for studies with at least two arms. Results Across 82 included studies, all grades rash (OR, 2.68; 95?% CI, 2.45-.94), hand-foot skin reaction (HFSR) (OR, 2.70; 95?% CI, 2.43-.00), and pruritus (OR, 1.25; 95?% CI, 1.12-.39) were associated with anti-VEGFR TKIs. Vandetanib had the highest incidence of rash (41?%), while sorafenib was most commonly associated with HFSR (37?%) and pruritus (14?%). The incidence of HFSR from 2000 to 2013 showed an upward trend (r 2--.042, p--.10) and in sunitinib therapy increased significantly (r 2--.237, p--.04). Conclusion The incidence of HFSR, rash, and pruritus varies considerably by drug. Our data suggest a continued need to address skin toxicities and improve reporting strategies.